Loading...
NPI 1346224409 · Louisville, KY · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Steven Bloom is a ophthalmology physician provider located in Louisville, Kentucky. This profile covers 17 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Steven Bloom |
| Address | 1935 Bluegrass Ave |
| City | Louisville |
| State | KY |
| ZIP | 40215 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | December 2, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.3M |
| Medicaid | $232K |
This provider’s revenue is heavily Medicare‑weighted: total Medicare revenue is $2.3M compared with total Medicaid revenue of $232K, making Medicare the dominant payer in absolute scale for this practice. The difference in scale suggests the business model and reimbursement mix are driven primarily by Medicare-covered services rather than Medicaid.
The practice appears clinically focused on retinal care and intravitreal therapy: the top Medicare revenue drivers are J2777, J0178, and 67028, which together account for 82.3% of Medicare revenue and correspond to biologic intravitreal injections and vitreous chamber injection procedures. That code mix, combined with high volumes of retinal imaging (92134) and frequent E/M visits, is consistent with a retina‑oriented ambulatory ophthalmology operation that pairs therapeutic injections with diagnostic imaging and follow-up visits.
Medicare revenue concentration is high: J2777 alone represents 47.1% of Medicare revenue while J0178 contributes 27.3% and 67028 contributes 7.9%, per the precomputed top‑3 share of 82.3%. J2777 shows very large claim count (36.9K claims) but is described as typical volume for that code nationally, whereas J0178 (902 claims) and 67028 (2K claims) are also meaningful contributors to the Medicare mix.
On Medicaid the revenue base is even more concentrated around the same service lines: 67028, 92134, and 99214 together account for 89.1% of the provider’s Medicaid revenue. Medicaid billing is led by 67028 at 43.9% of Medicaid revenue (679 claims) and by high counts for 92134 (1.8K claims) and 99214 (840 claims), signaling the same operational emphasis on injections, retinal imaging, and structured follow‑up visits in the Medicaid population.
Competitive standing varies by code: for Medicare this provider ranks in the 99th percentile and is an "extreme outlier, far above typical national volume" for 99214, and similarly is an "extreme outlier" for 92134 and J3590 (99th and 98th percentiles respectively), indicating unusually high volume of moderate‑complexity E/M visits, retinal imaging, and use of unclassified biologics compared with national peers. By contrast, J2777 (rank #191 of 2039, 91th percentile) and J0178 (rank #1384 of 3204, 57th percentile) are characterized as typical or unremarkable volumes nationally, so the practice mixes both unusually high E/M/imaging activity with otherwise typical biologic injection volumes.
Within the in‑state Medicaid competitive context this provider is a modest to solid participant on core codes: 67028 ranks #13 of 31 (60th percentile), 92134 ranks #10 of 74 (88th percentile), and 99214 ranks #1087 of 2462 (56th percentile). These ranks suggest the provider is a recognizable contributor to intravitreal injection and retinal imaging services in Kentucky but not a dominant statewide leader across all measured codes.
The billing profile shows substantial procedural throughput: high claim volumes are reported for key services on both payers—Medicare 92134 has 2.7K claims and 99214 has 1.3K claims, while Medicaid shows 1.8K claims for 92134 and 840 claims for 99214—supporting an operational picture of frequent imaging and follow‑up encounters that accompany injection therapy. This pattern underscores an ambulatory workflow with frequent diagnostic imaging and repeat visits associated with long‑term intravitreal treatment regimens.
The provider has an established clinical tenure, with an NPI enumerated on 2005‑12‑02 (~21 years ago), indicating long‑standing presence in the market. That longevity, combined with concentration in a narrow set of high‑revenue ophthalmologic services, suggests an experienced specialist practice focused on retinal therapeutics and monitoring rather than a broad comprehensive ophthalmology practice.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 36,900 | $30 | $1.1M |
| J0178 | Injection, aflibercept, 1 mg | 900 | $690 | $619.7K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,000 | $90 | $178.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,330 | $80 | $110.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,720 | $30 | $73.4K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 430 | $150 | $66.4K |
| J3590 | Unclassified biologics | 1,270 | $50 | $58.3K |
| J3490 | Unclassified drugs | 30 | $1,290 | $32.3K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 150 | $110 | $15.9K |
| 67210 | The provider destroys a lesion of the retina using a laser beam that heats up the tissue. | 40 | $370 | $15.1K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
17 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 20 | 40 | 870 | $690 | $858.5K |
| J2777 | 2 | 30 | 11,040 | $30 | $399.1K |
| 67028 | 5 | 50 | 650 | $90 | $72.9K |
| J7312 | 3 | 10 | 190 | $160 | $43.9K |
| J3490 | 13 | 10 | 50 | $370 | $27.2K |
| J3590 | 1 | 40 | 160 | $60 | $17K |
| 99214 | 34 | 7,230 | 110 | $70 | $14.1K |
| 67210 | 1 | 10 | 30 | $380 | $11.1K |
| 99213 | 1,972 | 7,250 | 80 | $50 | $7.7K |
| 67228 | 3 | 10 | 30 | $230 | $6.6K |
Showing 1–10 of 17
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 680 | $150 | $101.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,780 | $30 | $55.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 840 | $60 | $49.6K |
| J9035 | Injection, bevacizumab, 10 mg | 220 | $60 | $12.3K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 80 | $100 | $7.8K |
| 99203 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the provider… | 40 | $70 | $2.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 70 | $40 | $2.7K |
How this provider's Medicaid billing volume and revenue compare to other Kentucky providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Kentucky median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 2,793 | 3,340 | 1,020 | $30 | $296K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,087 | 2,460 | 580 | $40 | $245K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 13 | 30 | 350 | $70 | $165.3K |
| J9035 | Injection, bevacizumab, 10 mg | 6 | 20 | 120 | $130 | $96.1K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 610 | 1,020 | 120 | $70 | $62K |
| 99203 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the provider… | 1,029 | 1,400 | 130 | $50 | $45.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 10 | 70 | 210 | $20 | $29.2K |
Other providers in the same ZIP code as Steven Bloom, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Landmark Recovery Of Kentucky LLC | KY | Substance Abuse Rehabilitation Facility | $0 | $21.1M |
| Behavior Analysts Of Texas, LLC | KY | Behavior Analyst | $0 | $13.1M |
| Vip Imaging, PLLC | KY | Diagnostic Radiology Physician | $0 | $5.3M |
| Janelle Adeniran | KY | Ophthalmology Physician | $1.8M | $3.4K |
| Lewis Hargett | KY | Physical Medicine & Rehabilitation Physician | $103.6K | $685.6K |
| Denise Dickinson | KY | Dermatology Physician | $632.7K | $0 |
| John Millin | KY | Ophthalmology Physician | $457.5K | $43.5K |
| Adam Mueller | KY | Optometrist | $141.5K | $277.7K |
| Lawrence Tenkman | KY | Ophthalmology Physician | $383.7K | $0 |
| Nikolaos Zagorianos | KY | Optometrist | $283.5K | $3.3K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.